## FEB 2 7 2008

Atty. Dkt. No. 4343-101 2/27/2008

02-27-2008

## In the Claims

## **Listing of Claims**

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-11 (Cancelled).

- 12. (Currently Amended) A drug delivery device for oral administration, and colonic release, of an active agent, comprising:
  - a) an isolated active agent capable of inactivating an antibiotic, and
  - b) a drug delivery device suitable for administering the active agent to the colon.
- 13. (Original) The drug delivery device of Claim 12, wherein the active agent is an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 14. (Original) The drug delivery device of Claim 13, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
- 15. (Original) The drug delivery device of Claim 12, wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agent.
- 16. (Original) The drug delivery device of Claim 15, wherein the pectin is reticulated by a cationic polymer.
- 17. (Original) The drug delivery device of Claim 15, wherein the pectin salt is a calcium pectinate.
- 18. (Original) The drug delivery device of Claim 15, wherein the pectin is an amidated pectin.

Atty. Dkt. No. 4343-101 2/27/2008

- 19. (Withdrawn) A method of reducing the concentration of an antibiotic in the colon of a patient, comprising orally administering the drug delivery device of Claim 1 to a patient who has been, is being, or will be administered an antibiotic.
- 20. (Withdrawn) The method of Claim 19, wherein the active agent in the drug delivery device is an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 21. (Withdrawn) The method of Claim 20, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
- 22. (Withdrawn) The method of Claim 19, wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agent.
- 23. (Withdrawn) The method of Claim 22, wherein the pectin is reticulated by a cationic polymer.
  - 24. (Withdrawn) The method of Claim 22, wherein the pectin salt is a calcium pectinate.
  - 25. (Withdrawn) The method of Claim 22, wherein the pectin is an amidated pectin.
- 26. (Withdrawn) A method of preparing a drug delivery device for oral administration, and colonic delivery, of an active agent that inactivates an antibiotic, comprising:
- a) preparing a 4-10% (m/v) pectin solution that includes an active agent that inactivates an antibiotic,
- b) adding the pectin solution to a 2-10% (m/v) calcium chloride solution to form pectin cationically crosslinked beads, and
  - c) reticulating the pectin beads with a 0.5-2% (m/v) polyethylenimine solution.

9194199354

Atty. Dkt. No. 4343-101

- 27. (Withdrawn) The method of Claim 26, wherein the pectin solution further comprises a second active agent, where the second active agent is an antibiotic, an anti-inflammatory compound, an anti-histamine, an anti-cholinergic, an antiviral, an antimitotic, a peptide, a protein, a gene, an anti-sense oligonucleotide, a diagnostic agent, an immunosuppressive agent or a bacteria.
- 28. (Currently Amended) A drug delivery device comprising an isolated active agent capable of inactivating a macrolide, tetracycline or quinolone antibiotic.
- 29. (Original) The drug delivery device of Claim 28, wherein the device is suitable for administering the active agent to the colon.
- 30. (Original) The drug delivery device of Claim 28, wherein the active agent is an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 31. (Original) The drug delivery device of Claim 30, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
- 32. (Original) The drug delivery device of Claim 28, wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agent.
- 33. (Original) The drug delivery device of Claim 32, wherein the pectin is reticulated by a cationic polymer.
- 34. (Original) The drug delivery device of Claim 32, wherein the pectin salt is a calcium pectinate.
- 35. (Original) The drug delivery device of Claim 32, wherein the pectin is an amidated pectin.

Atty. Dkt. No. 4343-101 2/27/2008

- 36. (Original) The drug delivery device of Claim 28, further comprising a second active agent, wherein the second agent is an antibiotic, an anti-inflammatory compound, an anti-histamine, an anti-cholinergic, an antiviral, an antimitotic, a peptide, a protein, a gene, an antisense oligonucleotide, a diagnostic agent, an immunosuppressive agent or a bacteria.
- 37. (Withdrawn) A method of reducing the concentration of a macrolide, tetracycline or quinolone antibiotic in the colon of a patient, comprising orally administering an effective, antibiotic-reducing amount of the drug delivery device of Claim 28 to a patient who has been, is being, or will be administered a macrolide, tetracycline or quinolone antibiotic.
- 38. (Withdrawn) The method of Claim 37, wherein the drug delivery device administers the active agent to the colon.
- 39. (Withdrawn) The method of Claim 37, wherein the active agent in the drug delivery device is an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 40. (Withdrawn) The method of Claim 39, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
- 41. (Withdrawn) The method of Claim 37 wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agent.
- 42. (Withdrawn) The method of Claim 41, wherein the pectin is reticulated by a cationic polymer.
  - 43. (Withdrawn) The method of Claim 41, wherein the pectin salt is a calcium pectinate.
  - 44. (Withdrawn) The method of Claim 41, wherein the pectin is an amidated pectin.

- 45. (Currently Amended) A drug delivery device comprising:
  - a) a pectin and
  - b) an isolated active agent capable of inactivating an antibiotic.
- 46. (Original) The drug delivery device of Claim 45, wherein the device is suitable for administering the active agent to the colon.
- 47. (Original) The drug delivery device of Claim 45, wherein the active agent is an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 48. (Original) The drug delivery device of Claim 47, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
  - 49. (Original) The drug delivery device of Claim 45, further comprising a metal cation.
  - 50. (Original) The drug delivery device of Claim 49, wherein the cation is a calcium ion.
- 51. (Original) The drug delivery device of Claim 50, further comprising a cationic polymer.
- 52. (Original) The drug delivery device of Claim 45, wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agent.
- 53. (Original) The drug delivery device of Claim 52, wherein the pectin is reticulated by a cationic polymer.
- 54. (Original) The drug delivery device of Claim 52, wherein the pectin salt is a calcium pectinate.

Atty. Dkt. No. 4343-101 2/27/2008

- 55. (Original) The drug delivery device of Claim 52, wherein the pectin is an amidated pectin.
- 56. (Withdrawn) A method of reducing the concentration of an antibiotic in the colon of a patient, comprising orally administering an effective, antibiotic-reducing amount of the drug delivery device of Claim 45 to a patient who has been, is being, or will be administered an antibiotic.
- 57. (Withdrawn) The method of Claim 56, wherein the drug delivery device comprises an enzyme capable of inactivating macrolide or quinolone antibiotics.
- 58. (Withdrawn) The method of Claim 57, wherein the enzyme capable of inactivating macrolide antibiotics is erythromycin esterase.
  - 59. (Currently Amended) A drug delivery device comprising:
  - a) a first isolated active agent capable of inactivating an antibiotic, and
- b) a second active agent, where the second active agent is an antibiotic, an antiinflammatory compound, an anti-histamine, an anti-cholinergic, an antiviral, an antimitotic, a peptide, a protein, a gene, an anti-sense oligonucleotide, a diagnostic agent, an immunosuppressive agent or a bacteria.
- 60. (Original) The drug delivery device of Claim 59, wherein the device is suitable for administering the active agents to the colon.
  - 61. (Cancelled)
- 62. (Currently Amended) The drug delivery device of Claim 61 36, wherein the enzyme capable of inactivating macrolides is erythromycin esterase.

Atty. Dkt. No. 4343-101 2/27/2008

- 63. (Original) The drug delivery device of Claim 59, wherein the device comprises beads of pectin in the form of a cationic salt enclosing the active agents.
- 64. (Original) The drug delivery device of Claim 63, wherein the pectin is reticulated by a cationic polymer.
- 65. (Original) The drug delivery device of Claim 59, wherein the second active agent is specific for treating ulcerative colitis or Crohn's disease.
- 66. (Withdrawn) A method of reducing the concentration of an antibiotic in the colon of a patient, comprising orally administering an effective, antibiotic-reducing amount of the drug delivery device of Claim 60 to a patient who has been, is being, or will be administered an antibiotic.
- 67. (Withdrawn) The method of Claim 66, wherein the drug delivery device comprises an enzyme capable of inactivating macrolides or quinolones.
- 68. (Withdrawn) The method of Claim 67, wherein the enzyme capable of inactivating macrolides is erythromycin esterase.
- 69. (Withdrawn) The method of Claim 66, wherein the second active agent is specific for treating ulcerative colitis or Crohn's disease.